MELVILLE, NEW YORK--(Marketwired - Jan 25, 2016) - Millennium Healthcare Inc. (
UroVal is a leading edge, non-invasive healthcare product in the Uro/UroGyn arena, providing unique neurological insight into the health of S2-S4 pathways which control urinary, fecal and sexual function within the body. Additionally, the test itself is quick and easily administered and can be taken at the physician's office.
Dominick Sartorio, Millennium's Chairman, stated, "We are pleased to add yet another leading edge healthcare product to our growing list of products and services. UroVal provides patients with improved insight into their condition with minimal time, effort and discomfort and will be a great addition to Millennium's product line."
About Millennium Healthcare Inc. (www.millenniumhcs.com)
Millennium Healthcare Inc., through its wholly owned operating subsidiaries, provides primary care physician practices, physician groups and healthcare facilities of all sizes with cutting-edge medical devices focused primarily on preventive care through early detection. The Company also provides advanced billing and coding services, and practice development and management services. For more information, please visit www.millenniumhcs.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains certain statements that may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements are identified by such words and phrases as "we expect," "expected to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe," "could be," and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. Because they are forward-looking, they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.
JP Fortune Group